Mott David M
- SEC CIK
- 0001219871
In the past year, 1 open-market purchase filing worth $1.95M and no sales.
Current role at each company
- NVAX Novavax IncDirectoras of Jun 23, 2026
- ARDX Ardelyx, Inc.Directoras of Jun 18, 2026
- MRSN Mersana Therapeutics, Inc.Directoras of Jan 6, 2026
- ADAPY Adaptimmune Therapeutics PLCDirectoras of Jul 1, 2024
- EPZM Epizyme, Inc.Directoras of Aug 16, 2022
Show 1 more company
- ELVN Enliven Therapeutics, Inc.Directoras of Jun 3, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $1.95M
- 1 filing
- Sold
- –
- 0 filings
- Net
- +$1.95M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Mott David M as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ARDX Ardelyx, Inc.
Director10 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 (view filing) | Feb 20 | 3 days | Mott David MDirector | PPurchase | +333.3K | $5.84 | +$1.95M | +11.2%3.30M after | |
| Jun 18, 2025 (view filing) | Jun 16 | 2 days | Mott David MDirector | PPurchase | +200.0K | $3.63 | +$726.0K | +7.4%2.90M after | |
| Jun 11, 2025 (view filing) | Jun 9 | 2 days | Mott David MDirector | PPurchase | +200.0K | $3.69 | +$738.0K | +8.0%2.70M after | |
| May 19, 2025 (view filing) | May 15 | 4 days | Mott David MDirector | PPurchase | +100.0K | $3.29 | +$329.0K | +4.2%2.50M after | |
| May 5, 2025 (view filing) | May 2 | 3 days | Mott David MDirector | PPurchase | +381.4K | $4.22 | +$1.61M | +18.9%2.40M after | |
| Feb 26, 2025 (view filing) | Feb 24 | 2 days | Mott David MDirector | PPurchase | +77.7K | $5.00 | +$388.6K | +4.0%2.02M after | |
| Jan 22, 2025 (view filing) | Jan 21 | 1 day | Mott David MDirector | PPurchase | +199.0K | $4.99 | +$993.0K | +11.4%1.94M after | |
| Dec 23, 2024 (view filing) | Dec 19 | 4 days | Mott David MDirector | PPurchase | +213.3K | $4.67 | +$996.1K | +15.0%1.64M after | |
| Nov 14, 2024 (view filing) | Nov 13 | 1 day | Mott David MDirector | PPurchase | +215.9K | $4.62 | +$997.3K | +17.8%1.43M after | |
| Nov 17, 2022 (view filing) | Nov 17 | Same day | Mott David MDirector | PPurchase | +567.0K | $1.76 | +$997.9K | +94.5%1.17M after |
ELVN Enliven Therapeutics, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2022 (view filing) | Feb 18-23 | 5 days | Mott David MDirector | PPurchase | +151.5K | $1.45 | +$219.7K | +194.8%229.2K after | 3 lots |
| Feb 17, 2022 (view filing) | Feb 15-17 | 2 days | Mott David MDirector | PPurchase | +45.9K | $1.19 | +$54.7K | +144.3%77.8K after | 3 lots |
| Feb 14, 2022 (view filing) | Feb 10-14 | 4 days | Mott David MDirector | PPurchase | +31.8K | $1.23 | +$39.2K | New position31.8K after | 3 lots |
NVAX Novavax Inc
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2021 (view filing) | Sep 23 | 1 day | Mott David MDirector | SSale | −25.0K | $252.90 | −$6.31M | −38.4%40.0K after | 5 lots |